BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Durand CM, Bowring MG, Thomas AG, Kucirka LM, Massie AB, Cameron A, Desai NM, Sulkowski M, Segev DL. The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study. Ann Intern Med 2018;168:702-11. [PMID: 29710288 DOI: 10.7326/M17-2451] [Cited by in Crossref: 108] [Cited by in F6Publishing: 37] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, Kamkar N, Bahinskaya I, Onofrio FQ, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Schiff J, Reichman TW, McDonald M, Alba C, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HLA, Hansen BE, Singer LG, Humar A. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5:649-657. [PMID: 32389183 DOI: 10.1016/s2468-1253(20)30081-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
2 Notini L, Vasileva D, Orchanian-Cheff A, Buchman DZ. Ethical issues associated with solid organ transplantation and substance use: a scoping review. Monash Bioeth Rev 2019;37:111-35. [PMID: 31749129 DOI: 10.1007/s40592-019-00100-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Dollard SC, Annambhotla P, Wong P, Meneses K, Amin MM, La Hoz RM, Lease ED, Budev M, Arrossi AV, Basavaraju SV, Thomas CP. Donor-derived human herpesvirus 8 and development of Kaposi sarcoma among 6 recipients of organs from donors with high-risk sexual and substance use behavior. Am J Transplant 2021;21:681-8. [PMID: 32633035 DOI: 10.1111/ajt.16181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Cole H. The organ supply chain: Geography and the inequalities of transplant logistics. Trans Inst Br Geogr 2021;46:1008-21. [DOI: 10.1111/tran.12458] [Reference Citation Analysis]
5 Eckman MH, Adejare AA, Duncan H, Woodle ES, Thakar CV, Alloway RR, Sherman KE. Incorporating Patients' Values and Preferences Into Decision Making About Transplantation of HCV-Naïve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study. MDM Policy Pract 2021;6:23814683211056537. [PMID: 34734119 DOI: 10.1177/23814683211056537] [Reference Citation Analysis]
6 Leeser DB, Thomas AG, Shaffer AA, Veale JL, Massie AB, Cooper M, Kapur S, Turgeon N, Segev DL, Waterman AD, Flechner SM. Patient and Kidney Allograft Survival with National Kidney Paired Donation. Clin J Am Soc Nephrol 2020;15:228-37. [PMID: 31992572 DOI: 10.2215/CJN.06660619] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
7 Lafargue MC, Caliskan Y, Lentine KL, Riella LV. Opioids and Kidney Transplantation. Semin Nephrol 2021;41:42-53. [PMID: 33896473 DOI: 10.1016/j.semnephrol.2021.02.005] [Reference Citation Analysis]
8 Franco A, Moreso F, Sancho A, Esforzado N, Paul J, Llorente S, Crespo M, Guirado L, Melilli E, Roncero FG. Protocol for Optimizing the Use of Kidneys From Donors With Seropositivity for Hepatitis C Virus in Seronegative Recipients. Transplant Proc 2021;53:2655-8. [PMID: 34657711 DOI: 10.1016/j.transproceed.2021.09.013] [Reference Citation Analysis]
9 Soliman KM, Molini C, Novick T, Menez S, Fülöp T, Kraus E, Mcmahon BA. The impact of donor urine chemical toxicology analysis on outcomes of kidney transplantation. Int Urol Nephrol 2020;52:1173-8. [DOI: 10.1007/s11255-020-02450-w] [Reference Citation Analysis]
10 Ruck JM, Segev DL. Expanding deceased donor kidney transplantation: medical risk, infectious risk, hepatitis C virus, and HIV. Curr Opin Nephrol Hypertens 2018;27:445-53. [PMID: 30169460 DOI: 10.1097/MNH.0000000000000456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
11 Frye CC, Gauthier JM, Bery A, Gerull WD, Morkan DB, Liu J, Shea Harrison M, Terada Y, Van Zanden JE, Marklin GF, Pasque MK, Nava RG, Meyers BF, Patterson AG, Kozower BD, Hachem R, Byers D, Witt C, Kulkarni H, Kreisel D, Puri V. Donor management using a specialized donor care facility is associated with higher organ utilization from drug overdose donors. Clin Transplant 2021;35:e14178. [PMID: 33274521 DOI: 10.1111/ctr.14178] [Reference Citation Analysis]
12 Baran DA, Lansinger J, Long A, Herre JM, Yehya A, Sawey EJ, Badiye AP, Old W, Copeland J, Stelling K, Copeland H. Intoxicated Donors and Heart Transplant Outcomes: Long-Term Safety. Circ Heart Fail 2021;14:e007433. [PMID: 34315226 DOI: 10.1161/CIRCHEARTFAILURE.120.007433] [Reference Citation Analysis]
13 Callaghan CJ, Marks SD. Utilisation of kidneys from deceased donors at increased risk of infectious disease transmission: a step in the right direction. Pediatr Nephrol 2020;35:177-9. [PMID: 31667621 DOI: 10.1007/s00467-019-04380-x] [Reference Citation Analysis]
14 Bethea E, Arvind A, Gustafson J, Andersson K, Pratt D, Bhan I, Thiim M, Corey K, Bloom P, Markmann J, Yeh H, Elias N, Kimura S, Dageforde LA, Cuenca A, Kawai T, Safa K, Williams W, Gilligan H, Sise M, Fishman J, Kotton C, Kim A, Rogers CC, Shao S, Cote M, Irwin L, Myoung P, Chung RT. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020;20:1619-1628. [PMID: 31887236 DOI: 10.1111/ajt.15768] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
15 Kuntzen C, Bagha Z. The Use of Hepatitis C Virus–Positive Organs in Hepatitis C Virus–Negative Recipients. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.012] [Reference Citation Analysis]
16 Boyarsky BJ, Strauss AT, Segev DL. Transplanting Organs from Donors with HIV or Hepatitis C: The Viral Frontier. World J Surg 2021. [PMID: 33471156 DOI: 10.1007/s00268-020-05924-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Odenwald MA, Paul S. Viral hepatitis: Past, present, and future. World J Gastroenterol 2022; 28(14): 1405-1429 [DOI: 10.3748/wjg.v28.i14.1405] [Reference Citation Analysis]
18 Allana SS, Rajput FA, Smith JW, Lozonschi L, Liou JI, Johnson M, Kohmoto T, Dhingra R. Amiodarone Use Prior to Cardiac Transplant Impacts Early Post-Transplant Survival. Cardiovasc Drugs Ther 2021;35:33-40. [PMID: 33074524 DOI: 10.1007/s10557-020-07092-9] [Reference Citation Analysis]
19 Da BL, Ezaz G, Kushner T, Crismale J, Kakked G, Gurakar A, Dieterich D, Schiano TD, Saberi B. Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation. JAMA Netw Open 2020;3:e2027551. [PMID: 33275155 DOI: 10.1001/jamanetworkopen.2020.27551] [Reference Citation Analysis]
20 La Hoz RM, Sandıkçı B, Ariyamuthu VK, Tanriover B. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals. Am J Transplant 2019;19:3058-70. [PMID: 31207073 DOI: 10.1111/ajt.15496] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
21 Werbel WA, Durand CM. Pro: Use of Hepatitis C Virus-Positive Donors Should Be Considered Standard of Care. Clin Liver Dis (Hoboken) 2018;12:100-4. [PMID: 30988922 DOI: 10.1002/cld.743] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
22 Bowring MG, Jackson KR, Wasik H, Neu A, Garonzik-Wang J, Durand C, Desai N, Massie AB, Segev DL. Outcomes After Declining Increased Infectious Risk Kidney Offers for Pediatric Candidates in the United States. Transplantation 2019;103:2558-65. [PMID: 30801530 DOI: 10.1097/TP.0000000000002674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Alghamdi W, Lotfy K, Weernink C, Alsolami E, Jevnikar A, Luke P, Skaro A, Qumosani K, Brahmania M, Marotta P, Hosseini-moghaddam SM, Teriaky A. Hepatitis C positive organ transplantation to negative recipients at a multiorgan Canadian transplant centre: ready for prime time. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02107-1] [Reference Citation Analysis]
24 Bowring MG, Massie AB, Henderson M, Segev DL. Consent and labeling in the use of infectious risk donor kidneys: A response to "Information Overload". Am J Transplant 2018;18:2608-9. [PMID: 29920936 DOI: 10.1111/ajt.14975] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Potluri VS, Goldberg DS, Mohan S, Bloom RD, Sawinski D, Abt PL, Blumberg EA, Parikh CR, Sharpe J, Reddy KR, Molnar MZ, Sise M, Reese PP. National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. J Am Soc Nephrol. 2019;30:1939-1951. [PMID: 31515244 DOI: 10.1681/asn.2019050462] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
26 Holscher CM, Bowring MG, Haugen CE, Zhou S, Massie AB, Gentry SE, Segev DL, Garonzik Wang JM. National Variation in Increased Infectious Risk Kidney Offer Acceptance. Transplantation 2019;103:2157-63. [PMID: 31343577 DOI: 10.1097/TP.0000000000002631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Keenan S, Kramer A, Healey A, Weiss MJ, Dhanani S, Beed S, Djogovic D, Sullivan K, Shemie SD. The variable impact of the overdose crisis on organ donation among five Canadian provinces: a retrospective study. Can J Anaesth 2021;68:846-54. [PMID: 33564994 DOI: 10.1007/s12630-021-01945-z] [Reference Citation Analysis]
28 Yuan Q, Cui H, Leya GA, Hong S, Roth EM, Sise ME, Bethea ED, Yeh H, Williams WW, Elias N. Temporal trends and impact of willingness to accept organs from donors with hepatitis C virus. Transpl Int 2021;34:2562-9. [PMID: 34726801 DOI: 10.1111/tri.14152] [Reference Citation Analysis]
29 Foroutan F, Guyatt G, Friesen E, Lozano LEC, Sidhu A, Meade M. Predictors of 1-year mortality in adult lung transplant recipients: a systematic review and meta-analysis. Syst Rev 2019;8:131. [PMID: 31159866 DOI: 10.1186/s13643-019-1049-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Akintoye E, Alvarez P, Shin D, Egbe A, Panos A, Sellke F, Briasoulis A. Changing Demographics, Temporal Trends in Waitlist, and Posttransplant Outcomes After Heart Transplantation in the United States: Analysis of the UNOS Database 1991-2019. Circ Heart Fail 2021;14:e008764. [PMID: 34689572 DOI: 10.1161/CIRCHEARTFAILURE.121.008764] [Reference Citation Analysis]
31 Durand CM, Chattergoon MA. Bypassing the bottleneck: intentional hepatitis C transmission with organ transplant. J Clin Invest 2019;129:3038-40. [PMID: 31232703 DOI: 10.1172/JCI129982] [Reference Citation Analysis]
32 Jones JM, Kracalik I, Levi ME, Bowman JS 3rd, Berger JJ, Bixler D, Buchacz K, Moorman A, Brooks JT, Basavaraju SV. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020. MMWR Recomm Rep 2020;69:1-16. [PMID: 32584804 DOI: 10.15585/mmwr.rr6904a1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
33 Verna EC, Schluger A, Brown RS Jr. Opioid epidemic and liver disease. JHEP Rep 2019;1:240-55. [PMID: 32039374 DOI: 10.1016/j.jhepr.2019.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
34 Rochlani Y, Diab K, Jorde UP. Hepatitis C-Positive Donors in Cardiac Transplantation: Problems and Opportunities. Curr Heart Fail Rep 2020;17:106-15. [PMID: 32474734 DOI: 10.1007/s11897-020-00466-y] [Reference Citation Analysis]
35 Galasso M, Feld JJ, Watanabe Y, Pipkin M, Summers C, Ali A, Qaqish R, Chen M, Ribeiro RVP, Ramadan K, Pires L, Bagnato VS, Kurachi C, Cherepanov V, Moonen G, Gazzalle A, Waddell TK, Liu M, Keshavjee S, Wilson BC, Humar A, Cypel M. Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion. Nat Commun 2019;10:481. [PMID: 30696822 DOI: 10.1038/s41467-018-08261-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
36 Grubb CJ, Bergeria CL, Huhn AS, Dunn KE. Attitudes Toward Organ Donation for Persons Who Have a Substance Use Disorder Relative to Other Health Conditions. Front Psychiatry 2021;12:698645. [PMID: 34867506 DOI: 10.3389/fpsyt.2021.698645] [Reference Citation Analysis]
37 Strauss AT, Ishaque T, Weeks S, Hamilton JP, Simsek C, Durand CM, Massie AB, Segev DL, Gurakar A, Garonzik-Wang JM. Pretransplant Hepatitis C Virus Treatment Decreases Access to High-quality Livers. Transplant Direct 2021;7:e684. [PMID: 34549082 DOI: 10.1097/TXD.0000000000001127] [Reference Citation Analysis]
38 Cholankeril G, Li AA, Dennis BB, Toll AE, Kim D, Bonham CA, Nair S, Ahmed A. Increasing Trends in Transplantation of HCV-Positive Livers Into Uninfected Recipients. Clin Gastroenterol Hepatol 2019;17:1634-6. [PMID: 30268562 DOI: 10.1016/j.cgh.2018.09.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
39 Schlendorf KH, Zalawadiya S, Shah AS, Perri R, Wigger M, Brinkley DM, Danter MR, Menachem JN, Punnoose LR, Balsara K, Sacks SB, Ooi H, Awad JA, Sandhaus E, Schwartz C, O'Dell H, Carver AB, Edmonds CL, Ruzevich-Scholl S, Lindenfeld J. Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C. JAMA Cardiol 2020;5:167-74. [PMID: 31851352 DOI: 10.1001/jamacardio.2019.4748] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]
40 Bowring MG, Kucirka LM, Massie AB, Ishaque T, Bae S, Shaffer AA, Garonzik Wang J, Sulkowski M, Desai N, Segev DL, Durand CM. Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy. Transplantation 2018;102:2088-95. [PMID: 29912046 DOI: 10.1097/TP.0000000000002323] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
41 Bowring MG, Shaffer AA, Massie AB, Cameron A, Desai N, Sulkowski M, Garonzik-Wang J, Segev DL. Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States. Am J Transplant 2019;19:2329-41. [PMID: 30861279 DOI: 10.1111/ajt.15355] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
42 Woolley AE, Piechura LM, Goldberg HJ, Singh SK, Coppolino A, Baden LR, Mallidi HR. The impact of hepatitis C viremic donor lung allograft characteristics on post-transplantation outcomes. Ann Cardiothorac Surg 2020;9:42-8. [PMID: 32175238 DOI: 10.21037/acs.2020.01.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Ting PS, Hamilton JP, Gurakar A, Urrunaga NH, Ma M, Glorioso J, King E, Toman LP, Wesson R, Garonzik-Wang J, Ottmann S, Philosophe B, Sulkowski M, Cameron AM, Durand CM, Chen PH. Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients. Transpl Infect Dis 2019;21:e13194. [PMID: 31609520 DOI: 10.1111/tid.13194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
44 Moayedi Y, Gulamhusein AF, Khush KK. Treading lightly as we step into a new era: Use of hepatitis C virus-infected organs for transplantation. J Thorac Cardiovasc Surg 2020;159:505-10. [PMID: 31587888 DOI: 10.1016/j.jtcvs.2019.05.091] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Feld JJ, Ward JW. Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020. Hepatol Commun 2021;5:911-22. [PMID: 34141979 DOI: 10.1002/hep4.1731] [Reference Citation Analysis]
46 Kaltenbach MG, Harhay MO, Abt PL, Goldberg DS. Trends in deceased donor liver enzymes prior to transplant: The impact on graft selection and outcomes. Am J Transplant 2020;20:213-9. [PMID: 31420967 DOI: 10.1111/ajt.15573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
47 Shepherd HM, Gauthier JM, Puri V, Kreisel D, Nava RG. Advanced considerations in organ donors. J Thorac Dis 2021;13:6528-35. [PMID: 34992832 DOI: 10.21037/jtd-2021-08] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Sabra M, Ilonze O, Rao RA, Saleem K, Guglin ME. Donor substance abuse and heart transplantation outcomes. Heart Fail Rev 2022. [PMID: 35435527 DOI: 10.1007/s10741-022-10241-x] [Reference Citation Analysis]
49 Sapiano MRP, Jones JM, Bowman J, Levi ME, Basavaraju SV. Impact of US Public Health Service increased risk deceased donor designation on organ utilization. Am J Transplant 2019;19:2560-9. [PMID: 30959569 DOI: 10.1111/ajt.15388] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
50 Kim T, Chhabra N, Weech DM, Leikin JB. Short-Term Graft Failure of Organs Procured from Drug-Related Deaths Compared with Other Causes of Death. J Med Toxicol 2021;17:37-41. [PMID: 32789584 DOI: 10.1007/s13181-020-00801-8] [Reference Citation Analysis]
51 Meyers MR, Shults J, Laskin B, Porrett P, Levine M, Abt P, Amaral S, Goldberg DS. Use of public health service increased risk kidneys in pediatric renal transplant recipients. Pediatr Transplant 2019;23:e13405. [PMID: 31271263 DOI: 10.1111/petr.13405] [Reference Citation Analysis]